German biotechnology company BioNTech SE (Nasdaq:BNTX), the development partner with Pfizer for a COVID-19 vaccine, on 24 September 2020 joined other leading COVID-19 vaccine developers in ruling out participation in Britain's plans to test experimental inoculations by deliberately infecting trial volunteers.
According to a spokesman of the company, "BioNTech's vaccine candidate is not part of this study."
Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.
AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme, Reuters added.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100